Methods of Modulating Thrombocytopenia and Modified Transgenic Pigs
The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.
1 . A method of identifying a liver sinusoidal endothelial cell platelet uptake modulating compound comprising the steps of:
(a) providing liver sinusoidal endothelial cells;
(b) incubating a compound of interest with a first aliquot of liver sinusoidal endothelial cells;
(c) incubating a labeled platelet with said first aliquot of liver sinusoidal endothelial cell and a second aliquot of liver sinusoidal endothelial cells;
(d) monitoring platelet uptake into said liver sinusoidal endothelial cells;
(e) comparing platelet uptake by said liver sinusoidal endothelial cells in said first and second aliquots; and
(f) identifying said compound of interest as a liver sinusoidal endothelial cell platelet uptake modulating compound when there is a significant difference in platelet uptake by said liver sinusoidal endothelial cells in said first and second aliquots.
2 . A method of identifying a liver sinusoidal endothelial cell platelet uptake modulating compound comprising the steps of:
(a) providing liver sinusoidal endothelial cells;
(b) incubating a compound of interest with a first aliquot of liver sinusoidal endothelial cells;
(c) incubating a polymer particle coated with human platelet membranes with said first aliquot of liver sinusoidal endothelial cell and a second aliquot of liver sinusoidal endothelial cells;
(d) monitoring uptake of said polymer particle into said liver sinusoidal endothelial cells;
(e) comparing uptake of said polymer particle by said liver sinusoidal endothelial cells in said first and second aliquots; and
(f) identifying said compound of interest as a liver sinusoidal endothelial cell platelet uptake modulating compound when there is a significant difference in uptake of said polymer particle by said liver sinusoidal endothelial cells in said first and second aliquots.
3 . A method of modulating platelet uptake by liver sinusoidal endothelial cells comprising the steps of:
(a) providing a subject at risk for liver sinusoidal endothelial cell platelet uptake;
(b) administering a liver sinusoidal endothelial cell platelet uptake modulating compound.
4 . The method of claim 3 , wherein said liver sinusoidal endothelial cell platelet uptake modulating compound is administered to said subject.
5 . The method of claim 3 , wherein said subject is at risk because of exogenous platelet introduction.
6 . The method of claim 5 , wherein said liver sinusoidal endothelial cell platelet uptake modulating compound is incubated with said exogenous platelets prior to or concomitant with introduction of said platelets into said subject.
7 . The method of claim 3 , wherein said subject is at risk because of a liver transplant.
8 . A method of identifying a platelet binding related protein comprising the steps of:
(a) providing a liver sinusoidal endothelial cell;
(b) incubating a polymer particle coated with human platelet membranes with said liver sinusoidal endothelial cells;
(c) harvesting a phagosome comprising said polymer particle from said isolated liver sinusoidal endothelial cell;
(d) isolating said polymer particle from said phagosomes;
(e) analyzing a protein complex associated with said polymer particle; and
(f) identifying the proteins in said protein complex that comprises a protein of platelet origin and a protein of liver sinusoidal endothelial cell origin as platelet binding related proteins.
9 . A method of identifying a thrombocytopenia modulating compound comprising the steps of:
(a) providing liver sinusoidal endothelial cells;
(b) incubating a compound of interest with a first aliquot of liver sinusoidal endothelial cells;
(c) incubating a labeled platelet with said first aliquot of liver sinusoidal endothelial cells and a second aliquot of liver sinusoidal endothelial cells;
(d) monitoring platelet uptake into said liver sinusoidal endothelial cells;
(e) comparing platelet uptake by said liver sinusoidal endothelial cells in said first and second aliquots; and
(f) identifying said compound of interest as a thrombocytopenia modulating compound when there is a significant difference in platelet uptake by said liver sinusoidal endothelial cells in said first and second aliquots.
10 . A method of identifying thrombocytopenia modulating compounds comprising the steps of:
(a) providing liver sinusoidal endothelial cells;
(b) incubating a compound of interest with a first aliquot of liver sinusoidal endothelial cells;
(c) incubating a polymer particle coated with human platelet membranes with said first aliquot of liver sinusoidal endothelial cell and a second aliquot of liver sinusoidal endothelial cells;
(d) monitoring uptake of said polymer particle into said liver sinusoidal endothelial cells;
(e) comparing uptake of said polymer particle by said liver sinusoidal endothelial cells in said first and second aliquots; and
(f) identifying a compound of interest as a thrombocytopenia modulating compound when there is a significant difference in uptake of said polymer particle by said liver sinusoidal endothelial cells in said first and second aliquots.
11 . A method of modulating the asialoglycoprotein receptor-ligand interaction comprising the step of administering an asialoglycoprotein receptor modulating compound.
12 . The method of claim 11 , wherein said asialoglycoprotein receptor modulating compound is selected from the group comprising:
(a) an isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides that is substantially identical to 19 to 25 consecutive nucleotides set forth in SEQ ID NO:9; and
(b) an isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides comprising a sequence set forth in SEQ ID NO:11 and a second strand of nucleotides comprising a sequence substantially complementary to the first strand.
13 . A method of identifying an asialoglycoprotein receptor modulating compound comprising the steps of:
(a) providing liver sinusoidal endothelial cells;
(b) incubating a compound of interest with a first aliquot of liver sinusoidal endothelial cells;
(c) incubating a labeled platelet with said first aliquot of liver sinusoidal endothelial cells and a second aliquot of liver sinusoidal endothelial cells;
(d) monitoring platelet uptake into said liver sinusoidal endothelial cells;
(e) comparing platelet uptake by said liver sinusoidal endothelial cells in said first and second aliquots; and
(f) identifying said compound of interest as an asialoglycoprotein receptor modulating compound when there is a significant difference in platelet uptake by said liver sinusoidal endothelial cells in said first and second aliquots.
14 . A method of modulating liver sinusoidal endothelial cell platelet uptake comprising the steps of:
(a) providing a subject at risk for liver sinusoidal endothelial cell platelet uptake and
(b) administering an asialoglycoprotein receptor modulating compound.
15 . The method of claim 14 , wherein said asialoglycoprotein receptor modulating compound is selected from the group comprising:
(a) an isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides that is substantially identical to 19 to 25 consecutive nucleotides set forth in SEQ ID NO:9; and
(b) an isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides comprising a sequence set forth in SEQ ID NO:11 and a second strand of nucleotides comprising a sequence substantially complementary to the first strand.
16 . A method of modulating thrombocytopenia comprising the steps of:
(a) providing a subject at risk for thrombocytopenia and
(b) administering an asialoglycoprotein receptor modulating compound to said subject.
17 . A method of modulating liver sinusoidal endothelial cell platelet uptake comprising the steps of providing a transgenic animal comprising a disrupted ASGR1 gene in the nuclear genome of at least one cell of said animal wherein said disrupted ASGR1 gene is homozygous and a liver from said animal exhibits altered platelet uptake.
18 . The method of claim 17 , wherein said transgenic animal is a mammal selected from the group comprising simian, porcine, ovine, canine, equine, bovine, caprine, feline and lapine mammals.
19 . The method of claim 18 , wherein said transgenic mammal is porcine.
20 . The method of claim 17 wherein said transgenic animal exhibits reduced expression of said ASGR1 gene.
21 . The method of claim 17 , wherein said platelet uptake by a transgenic liver from said transgenic animal is reduced as compared to platelet uptake by a non-transgenic liver.
22 . The method of claim 17 , wherein said disrupted ASGR1 gene encodes a polypeptide having an amino acid sequence wherein the amino acid sequence of said polypeptide is selected from the group comprising:
(a) an amino acid sequence that differs by at least one amino acid from the amino acid sequence set forth in SEQ ID NO:10;
(b) an amino acid sequence having an amino acid other than glycine at position 262 of SEQ ID NO:10;
(c) an amino acid sequence having an arginine residue at position 262 of SEQ ID NO:10; and
(d) an amino acid sequence that differs by at least 1-20 amino acid residues from the amino acid sequence set forth in SEQ ID NO:10.
23 . A transgenic pig comprising a disrupted ASGR1 gene in the nuclear genome of at least one cell of said pig wherein said disrupted ASGR1 gene is homozygous and wherein a liver from said pig exhibits altered platelet uptake.
24 . A transgenic pig of claim 23 , wherein said disrupted ASGR1 gene encodes a polypeptide having an amino acid sequence wherein the amino acid sequence of said polypeptide is selected from the group comprising:
(a) an amino acid sequence that differs by at least one amino acid from the amino acid sequence set forth in SEQ ID NO:10;
(b) an amino acid sequence having an amino acid other than glycine at position 262 of SEQ ID NO:10;
(c) an amino acid sequence having an arginine residue at position 262 of SEQ ID NO:10; and
(d) an amino acid sequence that differs by at least 1-20 amino acid residues from the amino acid sequence set forth in SEQ ID NO:10.
25 . A method of modulating thrombocytopenia comprising the steps of:
(a) providing a subject at risk for thrombocytopenia and
(b) administering a Mac-1 inhibitor to said subject.
26 . A transgenic pig comprising a disrupted ASGR2 gene in the nuclear genome of at least one cell of said pig wherein said disrupted ASGR2 gene is homozygous and wherein a liver from said pig exhibits altered platelet uptake.
27 . A transgenic pig comprising a disrupted Mac-1 gene in the nuclear genome of at least one cell of said pig wherein said disrupted Mac-1 gene is homozygous and wherein a liver from said pig exhibits altered platelet uptake.
28 . An isolated double-stranded ribonucleic acid (dsRNA) molecule selected from the group comprising: (a) an isolated double-stranded (dsRNA) molecule comprising a first strand of nucleotides that is substantially identical to 19 to 25 consecutive nucleotides set forth in SEQ ID NO:9; and
(b) an isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides comprising a sequence set forth in SEQ ID NO:11 and a second strand of nucleotides comprising a sequence substantially complementary to the first strand.
29 . An isolated nucleic acid molecule comprising an expression control sequence operably linked to a nucleotide sequence that is a template for one or both strands of the dsRNA molecule of claim 28 .
30 . A transgenic pig comprising an isolated nucleic acid molecule comprising an expression control sequence operably linked to a nucleotide sequence that is a template for one or both strands of a siRNA molecule that inhibits expression of a nucleic acid molecule encoding ASGR1, wherein a liver from said transgenic pig exhibits reduced platelet uptake.
31 . An isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides and a second strand of nucleotides that is substantially complementary to the first strand that inhibits expression of a nucleic acid molecule encoding ASGR2.
32 . An isolated nucleic acid molecule comprising an expression control sequence operably linked to a nucleotide sequence that is a template for one or both strands of said isolated double-stranded ribonucleic acid molecule of claim 31 .
33 . A transgenic pig comprising an isolated nucleic acid molecule comprising an expression control sequence operably linked to a nucleotide sequence that is a template for one or both strands of a siRNA molecule that inhibits expression of a nucleic acid molecule encoding ASGR2, wherein a liver from said transgenic pig exhibits reduced platelet uptake.
34 . An isolated double-stranded ribonucleic acid (dsRNA) molecule comprising a first strand of nucleotides and a second strand of nucleotides that is substantially complementary to the first strand that inhibits expression of a nucleic acid molecule encoding Mac1.
35 . An isolated nucleic acid molecule comprising an expression control sequence operably linked to a nucleotide sequence that is a template for one or both strands of the isolated double-stranded ribonucleic acid molecule of claim 34 .
36 . A transgenic pig comprising an isolated nucleic acid molecule comprising an expression control sequence operably linked to a nucleotide sequence that is a template for one or both strands of a siRNA molecule that inhibits expression of a nucleic acid molecule encoding Mac1, wherein a liver from said transgenic pig exhibits reduced platelet uptake.